2024年11月7日,生物医药领域知名公司吉利德科学(GILD)股价盘中大涨5.12%,引发市场普遍关注。此前,吉利德公布了2024年第三季度业绩,营收达到75.5亿美元,同比增长7%,超出市场预期。调整后每股收益2.02美元亦高于分析师平均预期水平。
值得一提的是,由于药品销售增长强劲,吉利德科学上调了2024年全年业绩指引。公司预计全年营收将在278亿至281亿美元区间,调整后每股收益将介于4.25至4.45美元,均超出了此前的指引区间和市场预期。
投资者和分析师看好吉利德科学业绩持续向好的主要因素,是公司旗下新药如来那卡韦、Livdelzi等获批或即将上市。其中每年仅需注射两次的来那卡韦被视为艾滋病预防领域前景广阔的新药,公司计划在本年底前向美国FDA申请该药获批上市。多家券商就此上调了对吉利德的评级和目标股价,认为这款新药能极大提升吉利德科学在艾滋病预防领域的竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.